ACHN News and Press, Achison Inc Cl A From 07/23/19

Gainers : Therapix Biosciences (NASDAQ: TRPX ) +45% . Chiasma (NASDAQ: CHMA ) +31% . Achillion Pharmaceuticals (NASDAQ: ACHN ) +24% . Hoth Therapeutics (NASDAQ: HOTH ) +20% . Torchlight Energy Resources (NASDAQ: TRCH ) +17% . Realogy Holdings (NYSE: RLGY ) +16% . ClearSign Combustion...

Achillion Pharmaceuticals (NASDAQ: ACHN ) announces results from their Phase 1 multiple ascending dose study with ACH-5228 outside U.S. More news on: Achillion Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...

ACH-5228 delivers near complete and sustained inhibition of the complement alternative pathway Twice-daily oral administration to move forward in Phase 2 trials Investigational New Drug (IND) application to be submitted in fourth quarter of 2019 BLUE BELL, Pa., July 22, 2019 (...

Bill Mathews , founder and contributing editor to The Cheap Investor , selected Achillian Pharmaceuticals ( ACHN ) as a more speculative idea for 2019. The stock has risen 69%. Here's his latest update on this biotech firm. More from Bill Mathews: Biotech Bets (and a Go...

The following slide deck was published by Achillion Pharmaceuticals, Inc. in conjunction with this Read more ...

BLUE BELL, Pa., June 13, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that Brian Di Donato, Chief Fin...

BLUE BELL, Pa., June 10, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that the final data set for ACH...

SPDR Biotech ETF (NYSE: XBI ) provides investors diversified exposure to one of the most exciting industries in the market. Diversified is a relative term here because biotechnology companies, particularly those that are still in early stages of drug development, are often times the riskie...

Achillion Pharmaceuticals ( ACHN ) has trended lower over the last two weeks despite reporting positive phase 2 results of ACH-4471 in combination with Soliris in PNH patients. The results look encouraging, but investors are either concerned with two safety events that resolved with patients...

Cray (NASDAQ: CRAY ) +17%  on being acquired by HPE. More news on: Cray Inc., Outlook Therapeutics, Inc., DropCar, Inc., Stocks on the move, Read more ...